Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
2.420
+0.030 (1.26%)
At close: Aug 6, 2026, 4:00 PM EDT
2.448
+0.028 (1.15%)
Pre-market: Aug 7, 2026, 7:00 AM EDT
Atossa Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
20.84M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 26.55M |
| Werewolf Therapeutics | 21.00M |
| Daré Bioscience | 1.16M |
| Pluri | 1.08M |
| Cocrystal Pharma | 225.00K |
| Neuphoria Therapeutics | -13.27K |
ATOS News
- 7 days ago - Atossa Therapeutics sees opportunities for (Z)-endoxifen beyond breast cancer - TheFly
- 7 days ago - Meet Atossa Therapeutics: Fly Exclusive with CFO Mark Daniel - TheFly
- 9 days ago - Atossa Therapeutics’ (Z)-endoxifen compounds show anti-breast cancer action - TheFly
- 9 days ago - Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer - PRNewsWire
- 16 days ago - Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers - PRNewsWire
- 4 weeks ago - Atossa Therapeutics initiated with a Buy at Rodman & Renshaw - TheFly
- 7 weeks ago - Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds - PRNewsWire
- 2 months ago - Atossa Therapeutics announces registered direct offering of up to $16.5M - TheFly